Kim et al. were the first to report a mechanistic link between ceramide and cathepsin B in regulating GCase activity and suggested that targeting lysosomal ceramide or cathepsin B is an important therapeutic strategy for activating GCase in PD and related disorders [178]. This evidence concerns the gene CTSB and Parkinson disease.